CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study Meeting Abstract

  

Authors:	Meric-Bernstam, F.; Lee, R. J.; Carthon, B. C.; Iliopoulos, O.; Mier, J. W.; Patel, M. R.; Tannir, N. M.; Owonikoko, T. K.; Haas, N. B.; Voss, M. H.; Harding, J. J.; Srinivasan, R.; Shapiro, G.; Telli, M. L.; Munster, P. N.; Carvajal, R. D.; Jenkins, Y.; Whiting, S. H.; Bendell, J. C.; Bauer, T. M.
Abstract Title:	CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study
Meeting Title:	2019 Genitourinary Cancers Symposium
Journal Title:	Journal of Clinical Oncology
Volume:	37
Issue:	7 Suppl.
Meeting Dates:	2019 Feb 14-16
Meeting Location:	San Francisco, CA
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2019-03-01
Language:	English
ACCESSION:	WOS:000489108800550
DOI:	10.1200/JCO.2019.37.7_suppl.549
PROVIDER:	wos
Notes:	Meeting Abstract: 549 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/156175